Navigation Links
BioMarin Announces Second Quarter 2011 Financial Results
Date:7/28/2011

ects to enroll approximately 160 patients across 40 centers worldwide and to report top-line results in the second half of 2012.
  • Kuvan Outcomes Study: PKU-016, a randomized, placebo-controlled, 13-week Kuvan outcomes study is ongoing.  Endpoints include clinically validated measures of neuropsychiatric symptoms and if successful, may enable a label amendment.  The company expects to report top-line results in the second half of 2012.
  • Hand-Held Blood Phe Monitor: Several programs are underway to expand and protect the market and to improve the ability of healthcare providers and patients to better manage PKU.  Regulatory clearance and commercial availability of the handheld blood Phe monitor are expected between the first quarter of 2013 and the third quarter of 2013.
  • Firdapse: BioMarin initiated a Phase III trial for LEMS in the U.S. in the second quarter of 2011.  

  • Mid-Stage Clinical Programs

  • PEG-PAL for PKU: Top-line results for the Phase II study, including a formulation study and the ongoing daily dosing study are expected in the third or fourth quarter of 2011.  The company expects to initiate a Phase III trial in the first or second quarter of 2012.

  • Early-Stage Clinical Programs

  • BMN-701 for Pompe Disease: BioMarin initiated a Phase I/II trial in Pompe patients in the first quarter of 2011.  The trial is an open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and clinical activity of BMN-701 administered as an intravenous infusion every two weeks at doses of 5 mg/kg, 10 mg/kg and 20 mg/kg.  The company expects to enroll up to 30 patients between the ages of 13 and 65 years old with late-onset Pompe disease for a treatment period of 24 weeks.  The primary objective of the study is to establish the maximum tolerated dose of every other week administration of BMN-701 and to trea
    '/>"/>

  • SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
    2. BioMarin Announces FDA Approval for Kuvan
    3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
    4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
    5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
    6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
    7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
    8. BioMarin to Present at the Oppenheimer Healthcare Conference
    9. BioMarin Announces Third Quarter 2009 Financial Results
    10. BioMarin to Acquire LEAD Therapeutics
    11. BioMarin to Present at the Credit Suisse Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/15/2014)... -- Investor-Edge has initiated coverage on the following ... and Company (NYSE: LLY ), Nektar Therapeutics (NASDAQ: ... and Novartis AG (NYSE: NVS ). Free research ... . On Friday, December 12, 2014, the NASDAQ ... Average lost 1.79%, to finish the day at 17,280.83, and ...
    (Date:12/15/2014)... , December 15, 2014 ... development company, is pleased to announce the grant of ... relating to its GPCR-focused drug discovery platform. ... strengthens the global patent estate covering Heptares, technologies and ... suite of patents recently granted by the US Patent ...
    (Date:12/13/2014)... HUNTSVILLE, Ala. , Dec. 12, 2014 /PRNewswire-USNewswire/ ... has purchased the HiSeq X Ten sequencing system ... will enable HudsonAlpha to produce and analyze genomic ... purchase stems from the Institute,s commitment to research ... The HiSeq X Ten provides unprecedented capacity, ...
    Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
    (Date:12/15/2014)... 2014 SIMpalm, a leading mobile ... for iPhone for its client, which allows users to ... company, specialized in finding the right wine. At ... uses combined sensory, chemistry and wine information. All this ... “wine fingerprint.” Those wines that are close counterparts to ...
    (Date:12/15/2014)... HealthDay Reporter FRIDAY, Dec. 12, ... the millions of American women who have migraine: The debilitating ... is no association between migraine and breast cancer risk," said ... Harvard Medical School. "There is no positive association, so there ... effect either." About 18 percent of American women and ...
    (Date:12/15/2014)... SIMSBURY, CT (PRWEB) December 15, 2014 ... in the prestigious Women World Awards in the category ... of a gold award for her weekly career blog ... and practical advice to help professionals elevate their talent ... Her blog, named after her book Networking Ahead ...
    (Date:12/15/2014)... CA (PRWEB) December 15, 2014 At ... the organizations AutismOne and Focus Autism ... enlighten attendees with research on the effects of toxins ... testing and intervention information. , Luminaries such as ... researchers from abroad with esteemed, credentialed colleagues of the ...
    (Date:12/15/2014)... La Jolla, Calif. (PRWEB) December 15, 2014 ... Roasters made the Coffee Review “Top 30 Coffees of 2014.” ... number two, and their Guji Zone Ethiopia at number 10. ... list twice. , Coffee Review’s selection is ranked on ... The Sumatra Ulos Batak scored 96 out of 100, and ...
    Breaking Medicine News(10 mins):Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
    ... clinic, injecting an anesthetic at certain points can reduce the ... is being presented today at the annual meeting of the ... Diego, had found that about 16% of patients encounter a ... was explained that the biopsies are commonly performed on men ...
    ... a new type of insulin that is inhaled rather ... respiratory infection or are exposed to passive smoke.// ... for treatment of diabetes. It uses an inhaler developed ... for healthcare providers," Professor Philippe Camus of the University ...
    ... the Queen’s Balmoral Castle in Scotland kills cancer cells and ... the University of Maribor in Slovenia said that they placed ... them to those placed in normal lab water. ,They ... cancer cells 62.5 percent more quickly than normal water. In ...
    ... nurses will be given ?5,000 to retrain ... Scotland. Health minister Andy Kerr said that ... million over two years on this plan.// ... nurses who are trained outside Europe and ...
    ... that "any disorder in human faculties" increases dependence on ... Abdul Kalam Wednesday urged researchers to "direct their efforts ... affected by autism".// ,Equality can be generated ... skills and engaging the minds of affected children in ...
    ... Fatigue is so common among Americans that it almost ... says that although the underlying cause of persistent fatigue ... fatigue is imaginary.// ,According to Boosting Your Energy, ... emotionally. Still, most people—even those being treated for fatigue-producing ...
    Cached Medicine News:Health News:Autistic Children Need Sense of Equality: A.P.J. Abdul Kalam 2Health News:Boosting Energy Naturally 2
    ... only test designed specifically for detecting ... pH. It includes a convenient pH ... range which is important in monitoring ... can now spend less time testing ...
    ... is recognized by medical professionals as the ... its accuracy, convenience and affordability. CLOtest was ... with Robin Warren, M.D. was the first ... and gastric ulcers. Today, CLOtest has become ...
    Rapid Urease test for the presumptive identification of H. pylori in gastric mucosal biopsies...
    ... Rapid Test Strip and Device are rapid ... antibodies to Helicobacter pylori (H. pylori) in ... in the diagnosis of H. pylori infection ... older. They are intended for health professionals ...
    Medicine Products: